GlassScriptPhysician profile
Florian T Walter
NPI 1407835192
$15,476.25
in general payments reported to CMS, 2019-2025
32 companies · $678 in 2025
The $678 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $33.16 · 2021: $87.30 · 2022: $538 · 2023: $13K · 2024: $562 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $2,247 · Gift: $22.84 · Travel and Lodging: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,092.99 |
| Food and Beverage | $2,247.46 |
| Gift | $22.84 |
| Travel and Lodging | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,556.99 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $468.23 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $454.89 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $368.05 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $299.14 | 2021-2022 | |
| Organon LLC | $167.05 | 2022-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $163.59 | 2022-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Bayer Healthcare Pharmaceuticals INC. | $99.61 | 2019-2025 | |
| Coopersurgical, INC. | $89.28 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Medtronic, INC. | $81.14 | 2023-2025 | Interstim, Micra, Parietene Ds |
| Gynesonics, INC. | $76.50 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Myriad Women'S Health, INC. | $75.86 | 2023 | Myrisk |
| Pfizer INC. | $69.15 | 2022-2024 | |
| Biogen, INC. | $53.27 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $46.90 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $39.81 | 2019-2025 | Slynd |
| Amag Pharmaceuticals, INC. | $34.40 | 2019 | |
| Ethicon US, LLC | $34.27 | 2022-2024 | Enseal, Harmonic |
| Allergan, INC. | $32.56 | 2019 | |
| Merck Sharp & Dohme LLC | $30.98 | 2019 | |
| Teleflex LLC | $29.87 | 2025 | Quikclot |
| Avion Pharmaceuticals | $28.92 | 2019 | |
| Csl Behring | $23.11 | 2023 | Kcentra |
| Duchesnay USA Incorporated | $22.37 | 2019 | |
| Mayne Pharma Commercial LLC | $22.13 | 2022 | |
| Kci USA, INC. | $21.79 | 2020 | |
| Integra Lifesciences Corporation | $17.58 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Daiichi Sankyo INC. | $15.20 | 2019 | |
| Gilead Sciences, INC. | $14.41 | 2025 | |
| Kerecis Limited | $14.09 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Minerva Surgical, INC | $13.98 | 2021 | |
| Lupin INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florian Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.